PLEASE READ THIS REQUEST

[wifeofvet]

it's looking like docalutamide (currently in stage 3 trials) is going to be the NEXT drug after Xtandi, probably not due to be on the market until late 2018...or even 2019.

Here's our problem. My husband needs it NOW. We requested a ''compassionate use'' designation. Bayer responded saying they have no compassionate use program for this drug DUE TO LACK OF REQUESTS.

here's the contact information:

Bayer Corporation

100 Bayer Boulevard

Whippany, NJ 07981

USA

Phone: [phone]

Please give it to your doctors and ask them to request it for compassionate use. even if YOU don't need it yet, your doctor most likely has a patient that DOES. the more requests they get, the bigger the chance that some of us will be able to get it early. the clinical trial prohibits people with two cancers to enroll in the trial...which is my husband's problem or he would be in the trial.

if you call the number their oncology dept will contact your doctor, most likely telling him ''not possible'' at this time. With ENOUGH REQUESTS they will probably make it available for compassionate use.

THANK YOU IN ADVANCE

[YostConner]

I will do as you request. Is there a trial of it available for your husband?

[AlanMeyer in reply to YostConner]

Yost,

Please note that the name of the drug may be darolutamide, see below.

Alan

[wifeofvet in reply to YostConner]

no...people with two cancers are not allowed in clinical trials

[AlanMeyer]

Hello,

I'm sorry to hear that your husband has run out of options.

I tried looking up docalutamide via Google but couldn't find any hits. I'm thinking the name is "Darolutamide", first studied under the name "ODM-201". It will be important to get the name right when calling doctors.

Here's a short abstract of the new drug with a link to a full article about it:

ncbi.nlm.nih.gov/pubmed/284...

Looking at the full article, the drug looks promising. My first thought was that it wouldn't improve on Xtandi because Xtandi is already a very powerful androgen receptor antagonist. However apparently some prostate cancer cells develop resistance to Xtandi but that resistance doesn't work against darolutamide. So maybe darolutamide will help.

I'm in full remission and don't have an oncologist to contact right now. The one who treated me moved to Canada. But maybe others here can help out.

Best of luck.

Alan

[Sisira in reply to AlanMeyer]

Appreciate your correction Alan.

Sisira

[wifeofvet]

you're right..it's darolutamide

[herb1]

Just read the abstract. It doesn't provide any data that would make one see a future--.

herb s

[wifeofvet in reply to herb1]

trust me. it's the next drug after xtandi. bayer has already partnered with Orion to produce it. it won't hurt you to ask your doctors to request a compassionate use program. let US be your guinea pig. we're desperate.

[herb1]

I hope you're right, I hope you're right.

herb

[gusgold]

Go to a major Oncology Center.....The Mayo Clinic can obtain Darolutamide for compassionate use when Xtandi and Zytiga have failed

Gus

[wifeofvet in reply to gusgold]

how do you know this?

[Dan59]

Good to hear of this, I remember when zytiga was showing good in Trials, just before it was approved It went for compassionate use. We all could not wait for it. If we do send letters there is a good chance it may be used for Compassionate use. I am just glad to hear there is something new coming out soon.

[Dan59]

Here is the only trial I can find on darolutamide, I would certainly not qualify, they require no previous lupron?LHRH agonist , no zytiga or xtandi ,or even ketoconazole., clinicaltrials.gov/ct2/show...

Dan

[wifeofvet in reply to Dan59]

yeah, that's for the trial. but, it will be the next drug for people who are failing xtandi (and all the others)

[Dan59 in reply to wifeofvet]

I hope it is, and that it works, seems pretty early as it is just a placebo controlled trial, and there does not seem to be the excitement there was about zytiga or xtandi with only one trial

Dan

[wifeofvet in reply to Dan59]

we'll try anything at this point.